AI Article Synopsis
- Psoriasis is a long-lasting inflammatory disease with no known cure, often requiring ongoing treatment, especially for moderate to severe cases.
- A study evaluated the long-term effectiveness of anti-TNFα biologic agents (infliximab, etanercept, adalimumab) in 210 psoriatic patients over a decade, finding that about one-third of them maintained good results with their treatments.
- The median survival rates for the treatments were approximately 9.5-10 years, suggesting these agents can be effective long-term, but more research is needed to identify factors affecting treatment success or failure over time.
Article Abstract
Psoriasis is a chronic, immune-mediated inflammatory disease for which no definitive cure exists and patients difficult to treat with moderate to severe psoriasis often require life-long therapy. In general, the use of any biologic agent as monotherapy allows a long-term efficacy, however survival response may progressively decrease over time. We report real-world long lasting response data in psoriatic patients on treatment with anti-TNFα evaluating those on the same anti-TNFα agent (infliximab, etanercept, adalimumab) from January 2011 and December 2013 to December 31, 2021 as monotherapy. On 210 treated patients, 69 were found to maintain the same anti-TNFα agent. The median survival rate for etanercept, infliximab and adalimumab was 10, 9.6, and 9.5 years respectively and the efficacy rate was similar (mean PASI96). Our results demonstrate that anti-TNFα agents are a long-term effective and safe therapeutic option for a satisfying proportion (33%) of patients with moderate-to-severe chronic plaque psoriasis. Further long-term real life studies are needed to better understand which are the causes of drug failure or persistent response and why these may occur at different time intervals in patients on the same drug.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.15956 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: A 73-year-old female with a 3 year history of Alzheimer's disease was treated within the protocol of The Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study (ACIST), an IRB approved clinical study registered with clinicaltrials.gov NCT03724136.
Method: The procedure consists of bone marrow aspiration, cell separation using an FDA cleared class 2 device, and intravenous and intranasal administration of the stem cell fraction.
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University of Cambridge, Cambridge, Cambridgeshire, United Kingdom.
Background: In the context of heightened attention to dementia, research gaps persist in the seamless integration of clinical and non-clinical care, including long-term support. This study aims to examine potential gaps in social support for US adults with cognitive impairment, focusing on the transition before and after a dementia diagnosis.
Methods: In this ambidirectional cohort study, we examined data from the Health and Retirement Survey(HRS) for US adults over 50, using data from 2000 to 2018.
Dementia Care Practice.
Alzheimers Dement
December 2024
Clinic of Cardiovascular Diseases named after Most Holy John Tobolsky, Moscow, Moscow, Russia.
Background: Most cerebrovascular lesions are aggravated by dementia. This study examines the possibility of reducing dementia by stimulating cerebral angiogenesis and neurogenesis using Transcatheter Intracerebral Laser Photobiomodulation Therapy (PBMT) in patients with Alzheimer's disease (AD), distal cerebral atherosclerosis, Binswanger's disease (BD), and vascular parkinsonism (VP).
Methods: The study included 404 patients with dementia, aged 29-81 (mean age 78).
The development and maintenance of immunity against visceral leishmaniasis.
Front Immunol
January 2025
Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Understanding the development and maintenance of immunological memory is important for efforts to eliminate parasitic diseases like leishmaniasis. Leishmaniasis encompasses a range of pathologies, resulting from infection with protozoan parasites belonging to the subgenera and of the genus A striking feature of these infections is that natural or drug-mediated cure of infection generally confers life-long protection against disease. The generation of protective T cell responses are necessary to control infections.
View Article and Find Full Text PDFZilebesiran and Hypertension: A Systematic Review and Meta-analysis.
J Saudi Heart Assoc
December 2024
College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Objectives: Zilebesiran is an investigational RNA interference therapeutic designed to lower blood pressure by targeting the hepatic production of angiotensinogen, the most upstream precursor of the renin-angiotensin-aldosterone system. This approach aims to offer long-lasting blood pressure control with potentially fewer doses compared to traditional antihypertensive medications. The objective of this systematic review and meta-analysis was to assess the antihypertensive efficacy of zilebesiran in patients with hypertension.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!